Disease activity, organ involvement, and treatment choice all shape infection risk in lupus and rheumatoid arthritis, with ...

In a new study, researchers found low glomerular filtration rate and chronic histologic damage predicted eGFR loss in people ...

In November 2024, the American College of Rheumatology (ACR) released a summary of their new guidelines for the screening, treatment, and management of lupus nephritis. What is important for a patient ...

Rheumatology and nephrology experts provide an overview of the pharmacologic treatment options in lupus nephritis and discuss recent FDA approved therapies belimumab and voclosporin. German Hernandez, ...

Medical experts illustrate characteristics in the presentation of lupus nephritis. Jorge Larranaga, MD: Lupus nephritis can present in several ways. Lupus may take up to 6 years to be diagnosed. About ...

Lupus low disease activity state is a valid treatment target for patients with lupus nephritis associated with renal function preservation. Achieving both Lupus Low Disease Activity State (LLDAS) and ...

In a large, real-world study, belimumab vs MMF use was associated with decreased odds of kidney failure outcomes, supporting its potential to slow progression. Belimumab is associated with markedly ...

Low-grade proteinuria (< 1 g/24 h) did not predict better renal outcomes or treatment response in patients with lupus nephritis, despite being associated with milder disease phenotypes.

Please provide your email address to receive an email when new articles are posted on . Early mycophenolate mofetil in newly diagnosed SLE led to fewer severe flares and lower incidence of lupus ...

The long-anticipated results of the Aspreva Lupus Management Study (ALMS) have finally been published. 1 The purpose of ALMS was to demonstrate the superiority of mycophenolate mofetil (MMF) over ...